Chronic neutrophilic leukemia with concurrent CSF3R and SETBP1 mutations: single colony clonality studies, in vitro sensitivity to JAK inhibitors and lack of treatment response to ruxolitinib

Leukemia. 2014 Jun;28(6):1363-5. doi: 10.1038/leu.2014.39. Epub 2014 Jan 21.

Authors

T L Lasho¹, A Mims², M A Elliott¹, C Finke¹, A Pardanani¹, A Tefferi¹

Affiliations

¹ Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
² Division of Hematology and Oncology, Medical University of South Carolina, Charleston, SC, USA.

PMID: 24445868
DOI: 10.1038/leu.2014.39

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antineoplastic Agents / therapeutic use
Breast Neoplasms / complications*
Breast Neoplasms / therapy
Carrier Proteins / genetics*
Combined Modality Therapy
Drug Resistance, Neoplasm / drug effects
Erythroid Cells / drug effects
Erythroid Cells / metabolism
Erythroid Cells / pathology
Female
Granulocytes / drug effects
Granulocytes / metabolism
Granulocytes / pathology
Humans
Hydroxyurea / therapeutic use
In Vitro Techniques
Janus Kinase 2 / antagonists & inhibitors*
Leukemia, Neutrophilic, Chronic / drug therapy
Leukemia, Neutrophilic, Chronic / etiology*
Leukemia, Neutrophilic, Chronic / pathology
Mutation / genetics*
Nitriles
Nuclear Proteins / genetics*
Prognosis
Pyrazoles / therapeutic use*
Pyrimidines
Receptors, Colony-Stimulating Factor / genetics*
Tumor Cells, Cultured

Substances

Antineoplastic Agents
CSF3R protein, human
Carrier Proteins
Nitriles
Nuclear Proteins
Pyrazoles
Pyrimidines
Receptors, Colony-Stimulating Factor
SETBP1 protein, human
ruxolitinib
JAK2 protein, human
Janus Kinase 2
Hydroxyurea